Goldman Sachs’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-259,941
| Closed | -$4.67M | – | 6673 |
|
|
2017
Q4 | $4.67M | Sell |
259,941
-493,303
| -65% | -$6.07M | ﹤0.01% | 3064 |
|
|
2017
Q3 | $8.89M | Buy |
753,244
+637,485
| +551% | +$7.15M | ﹤0.01% | 2655 |
|
|
2017
Q2 | $1.22M | Sell |
115,759
-70,254
| -38% | -$716K | ﹤0.01% | 4279 |
|
|
2017
Q1 | $2.05M | Buy |
186,013
+16,624
| +10% | +$193K | ﹤0.01% | 3727 |
|
|
2016
Q4 | $2.29M | Sell |
169,389
-43,372
| -20% | -$605K | ﹤0.01% | 3729 |
|
|
2016
Q3 | $2.62M | Buy |
212,761
+135,689
| +176% | +$1.6M | ﹤0.01% | 3599 |
|
|
2016
Q2 | $846K | Sell |
77,072
-71,665
| -48% | -$802K | ﹤0.01% | 4350 |
|
|
2016
Q1 | $1.63M | Buy |
148,737
+31,377
| +27% | +$396K | ﹤0.01% | 3667 |
|
|
2015
Q4 | $2.03M | Buy |
117,360
+105,451
| +885% | +$1.89M | ﹤0.01% | 3614 |
|
|
2015
Q3 | $237K | Sell |
11,909
-59,315
| -83% | -$1.36M | ﹤0.01% | 5839 |
|
|
2015
Q2 | $1.17M | Buy |
71,224
+46,985
| +194% | +$815K | ﹤0.01% | 4396 |
|
|
2015
Q1 | $377K | Buy |
24,239
+87
| +0.4% | +$1.35K | ﹤0.01% | 5415 |
|
|
2014
Q4 | $345K | Buy |
24,152
+5,832
| +32% | +$61.6K | ﹤0.01% | 5640 |
|
|
2014
Q3 | $119K | Buy |
18,320
+3,746
| +26% | +$24.9K | ﹤0.01% | 6501 |
|
|
2014
Q2 | $101K | Buy |
14,574
+4,016
| +38% | +$28.4K | ﹤0.01% | 6544 |
|
|
2014
Q1 | $75K | Sell |
10,558
-9,460
| -47% | -$81K | ﹤0.01% | 6482 |
|
|
2013
Q4 | $188K | Buy |
20,018
+7,683
| +62% | +$54.8K | ﹤0.01% | 5995 |
|
|
2013
Q3 | $77K | Buy |
12,335
+846
| +7% | +$5.28K | ﹤0.01% | 6224 |
|
|
2013
Q2 | $76K | Buy |
+11,489
| New | +$91.1K | ﹤0.01% | 5951 |
|
Other funds holding SCMP
Goldman Sachs's SCMP Position: Q1 2018 in Review
Goldman Sachs sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 259,941 shares — an estimated $4.67M sold.
Goldman Sachs first reported a position in SCMP in Q2 2013 and held it in 19 quarters. The position peaked at $8.89M in Q3 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.
- Goldman Sachs reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
- Goldman Sachs sold 259,941 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $4.67M.
- Goldman Sachs first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
- Goldman Sachs's Sucampo Pharmaceuticals, Inc. position peaked at $8.89M in Q3 2017.
- 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.
Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.